Press Releases
Excerpt from the Press Release: (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, August 24, 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces that…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE). “Over the past…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Aug. 19, 2021– Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s cerebrospinal fluid assay, CNSide™, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 17, 2021 /PRNewswire/ — Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. The new partnership will initially focus on SH-111, an oncology drug designed…
Read More
Excerpt from the Press Release: The U.S. Food and Drug Administration is informing patients, health care providers, and manufacturers about cybersecurity vulnerabilities with a “real-time operating system (RTOS)” designed by QNX and owned by BlackBerry. These vulnerabilities may introduce risks for certain medical devices and drug manufacturing equipment. FDA is not aware of any confirmed adverse events related to these vulnerabilities. Manufacturers…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune…
Read More
Excerpt from the Press Release: FREMONT, Calif., Aug. 5, 2021 /PRNewswire/ — Verseon today announced that VE-4840 will advance as the company’s primary diabetic retinopathy (DR) development candidate after it passed preliminary toxicology studies. Orally administered VE-4840 has also demonstrated significant reduction of diabetes-induced retinal vascular permeability (RVP) in vivo. These results, along with its excellent oral pharmacokinetics…
Read More
Excerpt from the Press Release: DUBLIN, Ireland and BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The collaboration…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide with five new planned Phase 2 and 3…
Read More
Excerpt from the Press Release: Emeryville, California, July 21, 2021 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of…
Read More